8 results match your criteria: "Acıbadem Maslak Hospital Assisted Reproductive Technologies Unit[Affiliation]"
Turk J Obstet Gynecol
December 2024
Acıbadem Maslak Hospital Assisted Reproductive Technologies Unit, Istanbul, Turkey.
Objective: Cessation of gonadotropin stimulation might affect follicular growth in patients in POSEIDON groups 3 and 4, which are unresponsive to high-dose stimulation.
Materials And Methods: In this retrospective study, data were extracted from the medical records of patients treated at the Acıbadem Maslak Hospital Assisted Reproductive Technologies Unit between November 2010 and December 2020. Eighty-five patients who fulfilled the inclusion criteria were included in the study.
Aim: To assess the efficacy of intratesticular injection of autologous platelet-rich plasma (PRP) in men with non-obstructive azoospermia (NOA) and a history of failed microdissection-testicular sperm extraction (mTESE) procedures.
Methods: A prospective case series of a cohort study was conducted involving couples diagnosed with NOA. Patients with at least one failed mTESE procedure were included.
Turk J Obstet Gynecol
September 2024
Acıbadem Maslak Hospital Assisted Reproductive Technologies Unit, İstanbul, Turkey.
Objective: This study aimed to determine whether the use of human chorionic gonadotropin (hCG) as a trigger could offer a potential solution for addressing empty follicle syndrome following the administration of a trigger for gonadotropin-releasing hormone agonist.
Materials And Methods: A retrospective cohort analysis was conducted using data extracted from the hospital database pertaining to 415 patients who underwent in vitro fertilization (IVF) with an antagonist protocol triggered by a gonadotropin-releasing hormone (GnRH) agonist between December 2019 and January 2023 at the Acıbadem Maslak Hospital Assisted Reproductive Technologies Unit. All cases that failed to obtain oocytes and required rescue were analyzed.
Hum Reprod
May 2024
IVIRMA Global Research Alliance, IVIRMA New Jersey, Basking Ridge, NJ, USA.
Study Question: Does intraovarian platelet-rich plasma (PRP) injection increase the number of mature oocytes obtained after controlled ovarian stimulation (COS) in young women with poor ovarian response (POR) undergoing IVF?
Summary Answer: Intraovarian PRP injection procedure does not improve mature oocyte yield after COS in women less than 38 years old with an established IVF history of POR.
What Is Known Already: POR is frequently encountered among the infertile population and the number of women seeking infertility treatment related to POR is increasing. Effective treatment options for this patient population to conceive with autologous oocytes are lacking.
Endocrine
January 2023
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, CT, USA.
Purpose: In this study, we investigated whether metabolic dysfunction in women with Polycystic ovarian syndrome (PCOS) induces granulosa cell (GC) stress and activates in the endoplamatic reticulum and the mitochondria (UPR and UPR, respectively).
Methods: Women who were diagnosed with PCOS (based on the Rotterdam criteria), were divided into two groups, PCOS with insulin resistance (PCOS-IR; n = 20) and PCOS with no insulin resistance (PCOS-nIR; n = 20), and compared to healthy oocyte donors (CONT; n = 20). Insulin resistance (IR) was assessed on the results of homeostasis model assessment (HOMA) that determines IR using the concentration of fasting plasma glucose and fasting insuline.
JBRA Assist Reprod
November 2022
Department of Obstetrics and Gynecology, Bezmialem Vakif University, Istanbul, Turkey.
Objective: The first aim of this study was to investigate the effect of apixaban on endometrial receptivity via immunohistochemical investigation of integrin β3 expression in pregnant rats. The second aim was to compare the endometrial effects of both subcutaneous and oral anticoagulant drugs in terms of integrin β3 expressions.
Methods: A total of 24 rats were selected for this study and divided into three equal groups as control, enoxaparin and apixaban groups.
Aging (Albany NY)
March 2022
IVI RMA New Jersey, Basking Ridge, NJ 07920, USA.
The aim of the current study was to characterize ovarian reserve parameters and IVF outcomes in women with a history of poor ovarian response (POR) treated with intraovarian injection of autologous platelet rich plasma (PRP). Reproductive age women (N=510; age range 30-45yo) diagnosed with POR based on Poseidon criteria were included in the study. PRP treatment resulted in higher AFC, higher serum AMH, lower serum FSH, and a higher number of mature oocytes and cleavage and blastocyst stage embryos.
View Article and Find Full Text PDFAging (Albany NY)
June 2020
IVI RMA New Jersey, Basking Ridge, NJ 07920, USA.
We aimed to determine whether intraovarian injection of autologous platelet rich plasma (PRP) improves response to ovarian stimulation and in vitro fertilization (IVF) outcome in women with primary ovarian insufficiency (POI). Women (N=311; age 24-40) diagnosed with POI based on ESHRE criteria underwent intraovarian PRP injection. Markers of ovarian reserve, and IVF outcome parameters were followed.
View Article and Find Full Text PDF